WUXI BIOLOGICS (CAYMAN) INC.
藥明生物技術有限公司*
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2269)

VOLUNTARY ANNOUNCEMENT
COMPLETION OF PRE-APPROVAL INSPECTION BY EMA

This announcement is made by WuXi Biologics (Cayman) Inc. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to keep shareholders and potential investors of the Company informed of the latest business developments of the Group.

The Company is pleased to announce that the European Medicines Agency (EMA) has completed the Pre-Approval Inspection (the "**Inspection**") of cGMP (Current Good Manufacturing Practice) drug substance (DS) and drug product (DP) facilities for the production of Trogarzo™ by TaiMed Biologics, the Company's partner, with no critical findings. The Company expects to submit its responses to the EMA inspection report in around March 2019 and obtain GMP approval (the "**Approval**") for its facilities in around May 2019.

EMA is a decentralised agency of the European Union (EU) responsible for the scientific evaluation, supervision and safety monitoring of medicines in the EU. The Company believes that the Inspection is the first of biomanufacturing industry in China by EMA and the Company will have the first cGMP biologics DS facility, the first cGMP biologics DP facility and the first cGMP cell banking facility in China to be approved by EMA for commercial manufacturing once the Approval is obtained. The DS and DP facilities were also approved by The Food and Drug Administration of the United States of America (U.S. FDA) in March 2018. With both U.S. FDA's and EMA's approval of the Group's biomanufacturing facility, the Company believes its status as a global leading biomanufacturing player will be greatly strengthened.

The Company is committed to continuously expand its global manufacturing footprint and improve its quality system so that the "Follow-the-Molecule" strategy will continue to accelerate and transform the process of the discovery, development and manufacturing of biologics. The Company believes that the Inspection will help to manifest the Group's world-class quality system that meets global quality standards and thereby benefits patients globally with biologics of better quality.

For and on behalf of
WuXi Biologics (Cayman) Inc.
Dr. Ge Li
Chairman

Hong Kong, February 19, 2019

As at the date of this announcement, the Board comprises Dr. Zhisheng Chen and Dr. Weichang Zhou as executive Directors; Dr. Ge Li, Mr. Edward Hu, Mr. Yibing Wu and Mr. Yanling Cao as non-executive Directors; and Mr. William Robert Keller, Mr. Teh-Ming Walter Kwauk and Mr. Wo Felix Fong as independent non-executive Directors.

* *For identification purpose only*